Study: Template-Based LND May Aid Local UTUC Control
Template-based lymph node dissection in patients with upper tract urothelial carcinoma could facilitate better local disease control by eliminating micrometastasis, according to investigators.
Genitourinary Cancer
Pembrolizumab Benefits Durable in BCG-Unresponsive High-Risk NMIBC
After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
Pathologic Stage at RNU Predicts Oncologic Outcomes in High-Grade UTUC
A study found no survival differences between high-grade UTUC patients who at the time of radical nephroureterectomy achieved low-grade disease following neoadjuvant chemotherapy and those who had inherently low-stage disease and did not receive chemotherapy.
Prioritizing Urologic Cancer Cases During the COVID-19 Pandemic
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
5-ARIs Do Not Lower Bladder Cancer Risk
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
Addition of Atezolizumab May Aid in Metastatic Urothelial Cancer
Phase 3 trial shows prolonged progression-free survival for atezolizumab plus platinum-based chemotherapy.
Neoadjuvant Chemo Possibly a Better Option in High-Grade UTUC Cases
Patients with high-grade upper tract urothelial carcinoma who respond to neoadjuvant chemotherapy have a reduced risk of death following surgery compared with those who receive adjuvant chemotherapy, a study found.
Jelmyto Approved for Low-Grade Upper Tract Urothelial Cancer
Approval was based on data from the ongoing open-label, single-arm, phase 3 OLYMPUS study.
Long-Term AEs Persist in Some Survivors of Testicular Cancer
A subset of testicular cancer survivors experience persistent, treatment-related, long-term adverse health outcomes that affect their ability to work.
Mitomycin C May Reduce Urothelial Recurrence Risk in UTUC
In a small study, single-dose instillation of mitomycin C immediately following therapeutic ureteroscopy for upper tract urothelial carcinoma was associated with an 87% decreased risk of urothelial recurrence.
-
Loading...
-
Loading...
Next post in Genitourinary Cancer
